Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Clinical evidence

AMPLIFIED

44 evidence topics · 11 sources

Objective
Location and study date
Study locations by state in the ClinicalTrials.gov record
StateLocations listed in the record
Alabama“Huntsville, Alabama, United States, 35805”
Florida“Hollywood, Florida, United States, 33023”; “Lauderdale Lakes, Florida, United States, 33313”; “Miami, Florida, United States, 33136”; “Orlando, Florida, United States, 32806”
Georgia“Columbus, Georgia, United States, 31904”; “Decatur, Georgia, United States, 30030”; “Fayetteville, Georgia, United States, 30214”; “Lawrenceville, Georgia, United States, 30046”; “Savannah, Georgia, United States, 31406”
Louisiana“Baton Rouge, Louisiana, United States, 70808”; “Metairie, Louisiana, United States, 70006”; “New Orleans, Louisiana, United States, 70121”; “Shreveport, Louisiana, United States, 71101”
Maryland“Silver Spring, Maryland, United States, 20901”
Mississippi“Columbus, Mississippi, United States, 39705”; “Tupelo, Mississippi, United States, 38801”
Nevada“Las Vegas, Nevada, United States, 89107”
New Jersey“Newark, New Jersey, United States, 07102”; “Newark, New Jersey, United States, 07103”
New York“Laurelton, New York, United States, 11413”; “New York, New York, United States, 10037”
North Carolina“Cary, North Carolina, United States, 27511”; “Chapel Hill, North Carolina, United States, 27599-7155”; “Durham, North Carolina, United States, 27710”; “New Bern, North Carolina, United States, 28562”
Pennsylvania“Philadelphia, Pennsylvania, United States, 19140”
South Carolina“Columbia, South Carolina, United States, 29203”; “Spartanburg, South Carolina, United States, 29306”
Texas“Dallas, Texas, United States, 75230”; “Dallas, Texas, United States, 75237”; “Dallas, Texas, United States, 75246”; “Dallas, Texas, United States, 75390”; “Houston, Texas, United States, 77054”
Virginia“Norfolk, Virginia, United States, 23504”
Study design
Design details in the ClinicalTrials.gov record
FieldRegistry value
Study type“Interventional”
Phase“Phase 2”
Primary purpose“Treatment”
Allocation“N/A”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Eligibility criteria
Age, sex, and healthy volunteers in the ClinicalTrials.gov record
FieldRegistry value
Ages eligible for study“18 Years to 67 Years”
Sexes eligible for study“All”
Accepts healthy volunteers“No”
Treatment
Study outcomes
Rationale for using percent change in UACR as the primary endpoint
Albuminuria change and kidney outcomes in APOL1-mediated kidney disease

“Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Statistical analysis description
Number of participants (Planned and analyzed)
Participants dosed and analyzed by cohort stated with the results
CohortEnrolled and dosedEfficacy analysisOn treatment with a week 13 assessment
Cohort 1: AMKD with modest proteinuria“N=23”“N=22”“18 and 14 people in cohort 1 and 2, respectively”
Cohort 2: AMKD with type 2 diabetes“N=18”“N=17”“18 and 14 people in cohort 1 and 2, respectively”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline UACR and UPCR by cohort
MeasureCohort 1: AMKD with modest proteinuriaCohort 2: AMKD with type 2 diabetes
Mean baseline UACR g/g (standard deviation)“0.28 (0.09)”“0.67 (0.87)”
Mean baseline UPCR g/g (standard deviation)“0.46 (0.20)”“1.12 (1.51)”
Efficacy results
Percent change in UACR and UPCR at week 13 by cohort
EndpointCohort 1: AMKD with modest proteinuriaCohort 2: AMKD with type 2 diabetes
Primary: geometric mean percent change in UACR at week 13 (95% confidence interval)“-42.7%”; “(-58.3%, -21.1%)”“-17.3%”; “(-36.3%, 7.2%)”
Other: geometric mean percent change in UPCR at week 13 (95% confidence interval)“-44.7%”; “(-60.9%, -21.9%)”“-25.4%”; “(-45.1%, 1.4%)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary: study limitations

AMPLIFIED was a single-arm, open-label study without a placebo or active comparator, so each cohort's result is a change from baseline over 13 weeks of inaxaplin 45 mg once daily added to “optimized standard of care”. Of 41 participants enrolled and dosed (23 in cohort 1 and 18 in cohort 2), 39 were in the efficacy analyses, and the week 13 analyses included 18 and 14 participants; the registry lists an actual enrollment of 42. The 95% confidence intervals “were generated post-hoc”, and in cohort 2 they include no change for both UACR (-36.3% to 7.2%) and UPCR (-45.1% to 1.4%). The design abstract planned 45 participants, including a third cohort of 15 participants with sickle cell disease, HIV, or lupus nephritis, which the results announcement does not report. The registry lists UACR as the only efficacy outcome measure, and UPCR is reported as an “other” endpoint. All 35 registered sites are in the United States, eligibility was limited to ages 18 to 67 years with eGFR of at least 25 mL/min/1.73 m2, and the only baseline characteristics reported are mean UACR and UPCR by cohort. The study measured no kidney function outcome. The AMKD-specific analysis supporting UACR change as a surrogate endpoint used 12-month changes in 128 participants without diabetes and with UACR of at least 420 mg/g, a range that excludes the cohort 1 eligibility range (UACR at least 100 to below 420 mg/g) and the cohort 2 population. As of 2026-11-15 the results are available only from company communications: the registry shows “No Results Posted”, and no peer-reviewed publication or congress presentation of the results was identified.